



\* \* \* \* \*  
 \* W E L C O M E T O T H E \*  
 \* U . S . P A T E N T T E X T F I L E \*  
 \* \* \* \* \*

=> s (blood or leukocyte# or cell#) (10n) (cryopreserv? or frozen) (p) (pyrogen# or interleukin# or cytokine#) (p) (elisa or immunoassay or bioassay or assay)

99768 BLOOD  
 7020 LEUKOCYTE#  
 260703 CELL#  
 719 CRYOPRESERV?  
 40145 FROZEN  
 4081 PYROGEN#  
 5664 INTERLEUKIN#  
 4145 CYTOKINE#  
 8539 ELISA  
 8039 IMMUNOASSAY  
 3618 BIOASSAY  
 49290 ASSAY  
 L1 4 (BLOOD OR LEUKOCYTE# OR CELL#) (10A) (CRYOPRESERV? OR FROZEN)  
 (P)  
 (PYROGEN# OR INTERLEUKIN# OR CYTOKINE#) (P) (ELISA OR IMMUNOA  
 SSA  
 Y OR BIOASSAY OR ASSAY)

=> d 1-4

1. 5,650,489, Jul. 22, 1997, Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof; Kit Sang Lam, et al., 530/334; 435/183; 436/86, 544; 530/300, 333, 344, 350, 806, 812, 817 [IMAGE AVAILABLE]
2. 5,635,365, Jun. 3, 1997, Noninvasive diagnosis for allograft rejection; Aftab A. Ansari, et al., 435/15, 30 [IMAGE AVAILABLE]
3. 5,510,240, Apr. 23, 1996, Method of screening a peptide library; Kit S. Lam, et al., 435/7.1, 4, 18, 23, 24; 436/86, 89, 90, 501, 518, 524, 528, 531; 530/350, 387.1 [IMAGE AVAILABLE]
4. 5,322,787, Jun. 21, 1994, Cytokine and bioassay therefor; Michael Martin, et al., 435/372, 29 [IMAGE AVAILABLE]

=> d kwic 1-4

US PAT NO: 5,650,489 [IMAGE AVAILABLE] L1: 1 of 4

DETDESC:

DETD(128)

The **bioassay** can be made with the Ba/F3-T recombinant cell line expressing erythropoietin receptor (EPO-R). These cells are dependent on the presence of either **interleukin-3** (IL-3) or EPO. Culture of these cells in the presence of IL-3 (supplied as 10% (v/v) WEHI-conditioned culture medium) will prevent the possible interference of EPO in the medium with the **bioassay**. Basic growth medium for Ba/F3-T cells is RPMI 1640 medium containing 2.0 g/L NaHCO<sub>3</sub> 10% (v/v) fetal bovine

serum, 1x. . . is prepared by culturing WEHI cells to confluence in the same basic medium. The conditioned medium is centrifuged to remove **cells**, passed through a 0.22  $\mu$ m filter and stored **frozen**. The Ba/F3-T **cells** are cultured to give  $1.31 \times 10^7$  cells, which will be distributed as  $1 \times 10^3$  cells/well in a volume of 150  $\mu$ l as. . .

US PAT NO: 5,635,365 [IMAGE AVAILABLE]

L1: 2 of 4

DETDESC:

DETD(44)

LAK cell medium is prepared for use in this **assay**; normal PBLs at 2 million per ml are cultured for 3 days at 37.degree. C., 7% CO<sub>2</sub> in RPMI 1640, gentamycin, L-glutamine, 10% heat-inactivated fetal calf serum, 1000 U/ml recombinant **interleukin 2** and then the **cells** are discarded after centrifugation. The conditioned medium is then **frozen** at -70.degree. C. in aliquots of 20 to 50 ml.

US PAT NO: 5,510,240 [IMAGE AVAILABLE]

L1: 3 of 4

DETDESC:

DETD(128)

The **bioassay** can be made with the Ba/F3-T recombinant cell line expressing erythropoietin receptor (EPO-R). These cells are dependent on the presence of either **interleukin-3** (IL-3) or EPO. Culture of these cells in the presence of IL-3 (supplied as 10% (v/v) WEHI-conditioned culture medium) will prevent the possible interference of EPO in the medium with the **bioassay**. Basic growth medium for Ba/F3-T cells is RPMI 1640 medium containing 2.0 g/L NaHCO<sub>3</sub> 10% (v/v) fetal bovine serum,  $1 \times 10^7$  . . . is prepared by culturing WEHI cells to confluence in the same basic medium. The conditioned medium is centrifuged to remove **cells**, passed through a 0.22  $\mu$ m filter and stored **frozen**. The Ba/F3-T **cells** are cultured to give  $1.31 \times 10^7$  cells, which will be distributed as  $1 \times 10^3$  cells/well in a volume of 150  $\mu$ l as. . .

US PAT NO: 5,322,787 [IMAGE AVAILABLE]

L1: 4 of 4

DETDESC:

DETD(5)

The **bioassay** may conveniently be provided in kit form. According to this aspect of the present invention, there is provided a kit for detecting a **cytokine** in a sample comprising in a compartment form a first compartment adapted to contain SPGM-1 cells and optionally additional compartments adapted to contain reagents for use in the method, such as IMDM, FCS, buffers and diluents. Preferably, the SPGM-1 **cells** are in **cryopreserved** form in the kit. Preferably, the SPGM-1 **cells** are **cryopreserved** at approximately  $10 \times 10^6$  -  $10 \times 10^7$  **cells**/ml and this may conveniently be packed in one or more vials containing from 0.1 to 100 ml, and preferably 1. . .

=> file jpo

FILE 'JPO' ENTERED AT 09:41:35 ON 20 NOV 1998

```

* * * * *
*               G P I
*   J A P A N E S E   P A T E N T   A B S T R A C T S
* * * * *

```

=> s 11

```

15590 BLOOD
389 LEUKOCYTE#
102025 CELL#
6 CRYOPRESERV?
8023 FROZEN
104 PYROGEN#
542 INTERLEUKIN#
87 CYTOKINE#
87 ELISA
972 IMMUNOASSAY
18 BIOASSAY
578 ASSAY
L2      0 (BLOOD OR LEUKOCYTE# OR CELL#) (10A) (CRYOPRESERV? OR FROZEN)
(P)
        (PYROGEN# OR INTERLEUKIN# OR CYTOKINE#) (P) (ELISA OR IMMUNOA
SSA
        Y OR BIOASSAY OR ASSAY)

```

=> file epoabs

FILE 'EPOABS' ENTERED AT 09:41:46 ON 20 NOV 1998

```

* * * * *
*   E U R O P E A N   P A T E N T   A B S T R A C T S
* * * * *

```

=> s 11

```

16195 BLOOD
592 LEUKOCYTE#
62714 CELL#
61 CRYOPRESERV?
3647 FROZEN
141 PYROGEN#
737 INTERLEUKIN#
380 CYTOKINE#
185 ELISA
1704 IMMUNOASSAY
68 BIOASSAY
3969 ASSAY
L3      0 (BLOOD OR LEUKOCYTE# OR CELL#) (10A) (CRYOPRESERV? OR FROZEN)
(P)
        (PYROGEN# OR INTERLEUKIN# OR CYTOKINE#) (P) (ELISA OR IMMUNOA
SSA
        Y OR BIOASSAY OR ASSAY)

```

=> logoff y

U.S. Patent & Trademark Office LOGOFF AT 09:41:57 ON 20 NOV 1998